Drug Profile
Methylphenidate plus - K-PAX Pharmaceuticals
Alternative Names: KPAX-002Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator K-PAX Pharmaceuticals
- Class Amino acids; Nootropics; Phenylacetates; Piperidines
- Mechanism of Action Adrenergic receptor modulators; Central nervous system stimulants; Dopamine release stimulants; Mitochondrial protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic fatigue syndrome; Persian-gulf-syndrome
Most Recent Events
- 07 Dec 2022 NDR batch #26 - Since the NCT status is unknown and no new development is indicated on the company website or pipeline, the NDR has been updated based on NCT.
- 07 Dec 2022 No development reported - Phase-II for Chronic fatigue syndrome in USA (PO) (NCT01966276)
- 07 Dec 2022 No development reported - Phase-II for Persian Gulf syndrome in USA (PO) (NCT02357030)